How to Avoid a Bone Marrow Biopsy when Monitoring Minimum Residual Disease in Multiple Myeloma: Hope for the Future!
H. Robert Bergen, III
Therapeutic effectiveness in multiple myeloma (MM) currently requires monitoring the relevant myeloma cells in a bone marrow sample. Because these plasma cell clones are producing a clonal antibody we sought to identify the antibody the clone was producing directly. Utilizing blood plasma where the M-protein is >0.8g/dL we have been able to identify unique tryptic peptides corresponding to immunoglobulin light chain variable regions belonging to each patients clone. Subsequent blood samples are utilized to measure MRD and the target peptide corresponding to each patients clone is monitored.
Presented at MSACL 2016 US